LncRNA LOXL1-AS1 promotes esophageal squamous cell carcinoma progression by targeting DESC1

Li, Hongle; Chu, Jie; Jia, Jinlin; Sheng, Jinxiu; Zhao, Xue; Xing, Yurong; He, Fucheng

doi:10.7150/jca.51136

Cited by 10 publications

(9 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SOCS2AS1 promotes tumour progression in prostate cancer [52] but inhibits tumour progression in epithelial, ovarian, and colorectal cancer [53][54][55]. USP2AS1 is a cancer-promoting factor that promotes tumour progression by diferent mechanisms in various types of tumours, including ovarian and colorectal cancer [56][57][58]. FGF14AS2 inhibits tumour progression in many ways, such as inhibiting metastasis by regulating the miR-370-3p/FGF14 axis [59].…”

Section: Discussionmentioning

confidence: 99%

Identification and Characterization of an Ageing-Associated 13-lncRNA Signature That Predicts Prognosis and Immunotherapy in Hepatocellular Carcinoma

Xue

2023

Journal of Oncology

View full text Add to dashboard Cite

Background. In cancer pathology, cell senescence not only alters cell function but also reshapes the immune microenvironments in tumours. However, the association between cell senescence, tumour microenvironment, and disease progression of hepatocellular carcinoma (HCC) is yet to be fully understood. Therefore, the role of cell senescence-related genes and long noncoding RNAs (lncRNAs) in evaluating the clinical prognosis and immune cell infiltration (ICI) of HCC patients requires further investigation. Methods. The limma R package was utilised to investigate differentially expressed genes according to the multiomics data. The CIBERSORT R package was utilised to assess ICI, and unsupervised cluster analysis was conducted using the R software’s ConsensusClusterPlus package. A polygenic prognostic model of lncRNAs was constructed by conducting univariate and least absolute shrinkage and selection operator (Lasso) cox proportional-hazards regression analyses. The time-dependent receiver operating characteristic (ROC) curves were used for validation. We utilised the survminer R package to evaluate the tumour mutational burden (TMB). Moreover, the gene set enrichment analysis (GSEA) helped in pathway enrichment analysis, and the immune infiltration level of the model was evaluated using the IMvigor210 cohort. Results. The identification of 36 prognosis-related genes was achieved based on their differential expression between healthy and liver cancer tissues. Liver cancer individuals were categorised into 3 independent senescence subtypes using the gene list, revealing considerable survival differences (variations). We observed that the prognosis of patients in the ARG-ST2 subtype was substantially better as compared to that in the ARG-ST3 subtype. Differences were observed in gene expression profiles among the three subtypes, with the differentially expressed genes predominantly associated with cell cycle control. The enrichment of upregulated genes in the ARG-ST3 subtype was observed in pathways related to biological processes, for instance, organelle fission, nuclear division, and chromosome recombination. ICI in the ARG-ST1 and ARG-ST2 subtypes, with relatively better prognosis, was substantially higher as compared to the ARG-ST3 subtype. Furthermore, a risk-score model, which can be employed as a reliable prognostic factor in an independent manner for individuals suffering from liver cancer, was constructed based on 13 cell senescence-related lncRNAs (MIR99AHG, LINC01224, LINC01138, SLC25A30AS1, AC006369.2, SOCS2AS1, LINC01063, AC006037.2, USP2AS1, FGF14AS2, LINC01116, KIF25AS1, and AC002511.2). The individuals with higher risk scores had noticeably poor prognoses in contrast with those having low-risk scores. Moreover, increased levels of TMB and ICI were observed in individuals with low-risk scores and gaining more benefit from immune checkpoint therapy. Conclusion. Cell senescence is an essential factor in HCC onset and progression. We identified 13 senescence-related lncRNAs as HCC prognostic markers, which can help understand their function in the onset and progression of HCC and guide clinical diagnosis and treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification and Characterization of an Ageing-Associated 13-lncRNA Signature That Predicts Prognosis and Immunotherapy in Hepatocellular Carcinoma

Xue

2023

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…In retinoblastoma (RB), LOXL1-AS1 can also act as an oncogene to regulate MAPK signaling pathway, promote RB proliferation and invasion and inhibit cell apoptosis [ 68 ]. LOXL1-AS1 is also highly expressed in renal cell carcinoma (RCC) [ 69 ], esophageal squamous cell carcinoma (ESCC) [ 70 ], thymic carcinoma (TC) [ 71 ], pancreatic carcinoma (PC) [ 72 ] and endometrial carcinoma (EC) [ 17 ], promoting tumor progression. In summary, these studies reveal that LOXL1-AS1 has carcinogenic effects on a variety of malignant tumors, but more in-depth research is needed.…”

Section: Role Of Loxl1-as1 In Various Cancersmentioning

confidence: 99%

“…Using qRT-PCR to detect the expression of DESC1 in ESCC cells after LOXL1-AS1 knockout, we found that DESC1 was significantly up-regulated. These findings suggest that DESC1 is an important downstream effect factor of LOXL1-AS1 in regulating the progression of ESCC, so LOXL1-AS1 is expected to become a new target for the treatment of ESCC through its interaction with DESC1 protein [ 70 ].…”

Section: Role Of Loxl1-as1 In Various Cancersmentioning

confidence: 99%

“…Using modern technology, we detect lncRNAs expression in clinical tissue samples, which makes LOXL1-AS1 to be used as a biomarker for cancer diagnosis. As mentioned above, LOXL1-AS1 is highly expressed in tissue samples from most types of cancer, including EC [ 17 ], CRC [ 22 ], GC [ 27 ], HCC [ 34 ], PCa [ 38 ], NSCLC [ 42 ], OC [ 47 ], CC [ 52 ], BC [ 55 ], gliama [ 59 ], OS [ 64 ], CCA [ 65 ], laryngocarcinoma [ 66 ], medulloblastoma [ 67 ], RB [ 68 ], RCC [ 69 ], ESCC [ 70 ], TC [ 71 ], PC [ 72 ]. In normal tissues, LOXL1-AS1 expression is limited.…”

Section: Role Of Loxl1-as1 In Various Cancersmentioning

confidence: 99%

“…Several studies have also shown that the level of LOXL1-AS1 is negatively correlated with the overall survival rate of HCC [ 36 ] and glioma [ 59 ]. In addition, the higher the expression level of LOXL1-AS1, the later the TNM stage of EC [ 17 ], CRC [ 22 ], CC [ 53 ], BC [ 55 ], CCA [ 65 ] and ESCC [ 70 ], and most of them were accompanied with lymph node metastasis, indicating the poor prognosis. In CRC, higher levels of LOXL1-AS1 can predict liver metastasis of CRC [ 22 ].…”

Section: Role Of Loxl1-as1 In Various Cancersmentioning

confidence: 99%

See 2 more Smart Citations

Long non-coding RNA LOXL1-AS1: a potential biomarker and therapeutic target in human malignant tumors

Fu,

Ji,

Tang

et al. 2024

Clin Exp Med

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) are transcripts that contain more than 200 nucleotides. Despite their inability to code proteins, multiple studies have identified their important role in human cancer through different mechanisms. LncRNA lysyl oxidase like 1 antisense RNA 1 (LOXL1-AS1), a newly discovered lncRNA located on human chromosome 15q24.1, has recently been shown to be involved in the occurrence and progression of various malignancies, such as colorectal cancer, gastric cancer, hepatocellular carcinoma, prostate cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, breast cancer, glioma, thymic carcinoma, pancreatic carcinoma. LOXL1-AS1 acts as competitive endogenous RNA (ceRNA) and via sponging various miRNAs, including miR-374b-5p, miR-21, miR-423-5p, miR-589-5p, miR-28-5p, miR-324-3p, miR-708-5p, miR-143-3p, miR-18b-5p, miR-761, miR-525-5p, miR-541-3p, miR-let-7a-5p, miR-3128, miR-3614-5p, miR-377-3p and miR-1224-5p to promote tumor cell proliferation, invasion, migration, apoptosis, cell cycle, and epithelial–mesenchymal transformation (EMT). In addition, LOXL1-AS1 is involved in the regulation of P13K/AKT and MAPK signaling pathways. This article reviews the current understanding of the biological function and clinical significance of LOXL1-AS1 in human cancers. These findings suggest that LOXL1-AS1 may be both a reliable biomarker and a potential therapeutic target for cancers.

show abstract

Long noncoding RNAs with peptide‐encoding potential identified in esophageal squamous cell carcinoma: KDM4A‐AS1‐encoded peptide weakens cancer cell viability and migratory capacity

Zhou

Cheng

et al. 2023

Molecular Oncology

View full text Add to dashboard Cite

Currently, the knowledge of long noncoding RNA (lncRNA)‐encoded peptides is quite lacking in esophageal squamous cell carcinoma (ESCC). In this study, we simultaneously identified six lncRNA open reading frames (ORFs) with peptide‐coding abilities including lysine‐specific demethylase 4A antisense RNA 1 (KDM4A‐AS1) ORF by combining weighted gene co‐expression network analysis (WGCNA) for ESCC clinical samples, ribosome footprints, ORF prediction, mass spectrometry (MS) identification, and western blotting. KDM4A‐AS1 ORF‐encoded peptide reduced ESCC cell viability and migratory ability. Co‐immunoprecipitation and MS analysis revealed that KDM4A‐AS1‐encoded peptide specifically bound with 103 proteins in ESCC cells, and enrichment analysis suggested that peptide‐bound proteins were related to fatty acid metabolism and redox process. Cell and molecular experiments demonstrated that KDM4A‐AS1‐encoded peptide inhibited stearoyl‐CoA desaturase and fatty acid synthase expression, increased reactive oxygen species level, and reduced mitochondrial membrane potential in ESCC cells. In summary, multiple lncRNAs with translation potential were simultaneously identified by combining multiple approaches in ESCC, providing novel identification strategies for lncRNA‐encoded peptides. Moreover, lncRNA KDM4A‐AS1‐encoded peptide weakened ESCC cell viability and migratory capacity and functioned in fatty acid metabolism and redox process.

show abstract

LncRNA LOXL1-AS1 promotes esophageal squamous cell carcinoma progression by targeting DESC1

Cited by 10 publications

References 33 publications

Identification and Characterization of an Ageing-Associated 13-lncRNA Signature That Predicts Prognosis and Immunotherapy in Hepatocellular Carcinoma

Identification and Characterization of an Ageing-Associated 13-lncRNA Signature That Predicts Prognosis and Immunotherapy in Hepatocellular Carcinoma

Long non-coding RNA LOXL1-AS1: a potential biomarker and therapeutic target in human malignant tumors

Long noncoding RNAs with peptide‐encoding potential identified in esophageal squamous cell carcinoma: KDM4A‐AS1‐encoded peptide weakens cancer cell viability and migratory capacity

Contact Info

Product

Resources

About